东诚药业：聘任刘雅楠为公司证券事务代表

Group 1 - The company Dongcheng Pharmaceutical announced the appointment of Liu Yanan as the securities affairs representative, effective from the date of the board's approval until the end of the current board's term in 2025 [1] - For the first half of 2025, the company's revenue composition is entirely from the biopharmaceutical industry, with a 100.0% share [1]